Back
5
Day Range
$7.17
$7.17
52-Week Range
$7.17
$8.66
Volume
1
50D / 200D Avg
$7.17
/
$7.40
Prev Close
$7.17
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 0.5 | 0.4 |
| P/B | 0.1 | 2.9 |
| ROE % | 16.0 | 3.8 |
| Net Margin % | 6.6 | 3.9 |
| Rev Growth 5Y % | 5.6 | 10.0 |
| D/E | 1.2 | 0.2 |
Key Takeaways
Revenue grew 5.58% annually over 5 years — modest growth
Earnings grew 16.28% over the past year
ROE of 15.99% — decent returns on equity
Generating 122.15M in free cash flow
P/E of 0.49 — trading at a low valuation
PEG of 0.52 suggests growth is underpriced
Growth
Revenue Growth (5Y)
5.58%
Revenue (1Y)4.53%
Earnings (1Y)16.28%
FCF Growth (3Y)-68.68%
Quality
Return on Equity
15.99%
ROIC8.52%
Net Margin6.62%
Op. Margin10.28%
Safety
Debt / Equity
1.19
Current Ratio1.15
Interest Coverage42.22
Valuation
P/E Ratio
0.49
P/B Ratio0.08
EV/EBITDA4.40
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 4.53% | Revenue Growth (3Y) | 5.43% |
| Earnings Growth (1Y) | 16.28% | Earnings Growth (3Y) | 17.76% |
| Revenue Growth (5Y) | 5.58% | Earnings Growth (5Y) | 22.70% |
| Profitability | |||
| Revenue (TTM) | 26.34B | Net Income (TTM) | 1.74B |
| ROE | 15.99% | ROA | 5.96% |
| Gross Margin | 49.70% | Operating Margin | 10.28% |
| Net Margin | 6.62% | Free Cash Flow (TTM) | 122.15M |
| ROIC | 8.52% | FCF Growth (3Y) | -68.68% |
| Safety | |||
| Debt / Equity | 1.19 | Current Ratio | 1.15 |
| Interest Coverage | 42.22 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 0.49 | P/B Ratio | 0.08 |
| P/S Ratio | 0.03 | PEG Ratio | 0.52 |
| EV/EBITDA | 4.40 | Dividend Yield | 0.00% |
| Market Cap | 854.53M | Enterprise Value | 11.93B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 26.34B | 25.20B | 23.70B | 21.64B | 21.20B |
| Net Income | 1.74B | 1.50B | 1.26B | 1.01B | 769.00M |
| EPS (Diluted) | 12.70 | 10.88 | 9.40 | 7.20 | 5.40 |
| Gross Profit | 13.09B | 12.46B | 11.76B | 10.55B | 10.45B |
| Operating Income | 2.71B | 3.16B | 2.72B | 2.46B | 2.08B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 29.23B | 28.39B | 27.80B | 26.27B | 25.62B |
| Total Liabilities | 18.24B | 17.42B | 16.76B | 15.33B | 15.03B |
| Shareholders' Equity | 10.87B | 10.93B | 11.02B | 10.89B | 10.58B |
| Total Debt | 12.97B | 12.65B | 12.30B | 10.86B | 10.88B |
| Cash & Equivalents | 1.89B | 1.80B | 2.28B | 1.50B | 1.46B |
| Current Assets | 6.51B | 6.38B | 6.43B | 5.44B | 5.60B |
| Current Liabilities | 5.65B | 6.26B | 5.60B | 5.28B | 5.62B |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#595 of 657
Recent Activity
Entered
Contrarian Investing (David Dreman)
Mar 24, 2026